A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders

Journal of Child and Adolescent Psychopharmacology

Volumn 11, Issue 3, 2001, Pages 267-277

  Posey, D J ^a   Guenin, K D ^a   Kohn, A E ^a   Swiezy, N B ^a   McDougle, C J ^a  

^a RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MIRTAZAPINE;

ADOLESCENT; ADULT; AGGRESSION; ANXIETY NEUROSIS; ARTICLE; ASPERGER SYNDROME; AUTISM; AUTOMUTILATION; CAREGIVER; CHILD; CLINICAL ARTICLE; DEPRESSION; DEVELOPMENTAL DISORDER; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; MALE; MENTAL DEFICIENCY; OBESITY; RETT SYNDROME; SCORING SYSTEM; SOMNOLENCE; TREATMENT OUTCOME;

EID: 0034797067     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/10445460152595586     Document Type: Article

References (35)

1. The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects
2. Whole blood serotonin in autistic and normal subjects
3. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children
4. Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms
5. Assessment in multisite randomized clinical trials of patients with autistic disorder: The autism RUPP network
6. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study
7. Selective serotonin re-uptake inhibitors for the treatment of perseverative and mal-adaptive behaviours of people with intellectual disability
8. Comparison of haloperidol and behavior therapy and their interaction in autistic children
9. Neuroleptic-related dyskinesias in autistic children: A prospective, longitudinal study
10. Treatment of autistic disorder
11. Valvular heart disease associated with fenfluramine-phentermine
12. Fluoxetine treatment of children and adults with autistic disorder and mental retardation
13. The pharmacologic profile of mirtazapine
14. Effects of fluoxetine treatment in young children with idiopathic autism
15. An open-label study with mirtazapine in depressed patients who are SSRI treatment failures
16. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression
17. Risperidone and tardive dyskinesia
18. Mirtazapine in major depression with comorbid generalized anxiety disorder
19. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder
20. Serotonin metabolism and hypothalamic-pituitary function in children with infantile autism and minimal brain dysfunction
21. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: Factors associated with extrapyramidal symptoms
22. Serotonergic responsivity in male young adults with autistic disorder: Results of a pilot study
23. Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation
24. A double-blind placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders
25. Effects of tryptophan depletion in drug-free adults with autistic disorder
26. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder
27. Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration
28. The pharmacology of target symptoms associated with autistic disorder and other pervasive developmental disorders
29. Selection of an antidepressant: Mirtazapine
30. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children
31. Fenfluramine: Neurotoxicity
32. Mirtazapine safety and tolerability: Analysis of the clinical trials database
33. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: A pilot study